(NASDAQ:PMN), Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026 Cambridge, Massachusetts, Dec. 18, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), […]

(CNSX:NIOB),(CNSX:NIOB.CN),(Boerse Frankfurt – Freiverkehr:IOR),(OTC US:NIOMF),(Other OTC:NIOMF), Vancouver, British Columbia, Dec. 18, 2025 (GLOBE NEWSWIRE) — North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to announce that it has acquired additional mineral properties in Quebec. The Company has (i) extended the Seigneurie Property

(NASDAQ:AVXL), NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it has requested

(NASDAQ:RGEN), WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the J.P. Morgan 2026 Healthcare Conference, being held January 12 – 15 in San Francisco. Olivier Loeillot, President and Chief Executive Officer, will present an overview of

(NasdaqGM:FCEL), Fourth Quarter Fiscal 2025 Summary(All comparisons are year-over-year unless otherwise noted) Revenue of $55.0 million, compared to $49.3 million, an increase of approximately 12% Gross loss of $(6.6) million, compared to $(10.9) million, a decrease of approximately 39% Loss from operations of $(28.3) million, compared with $(41.0) million, a decrease of approximately 31% Net

(TSX:BCT),(NASDAQ:BCTX),(NASDAQ:BCTXW),(NASDAQ:BCTXZ), Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to new treatments for advanced cancers and long COVID BriaCell's Phase 3 clinical trial in metastatic breast cancer featured as “clinical trial to watch in 2026” BriaCell anticipates reporting top line data as early as

(TSX-V:ECR),(Boerse Frankfurt – Freiverkehr:6CA), VAL-D'OR, Quebec, Dec. 18, 2025 (GLOBE NEWSWIRE) — Cartier Resources Inc. (“Cartier” or the “Company“) (TSXV: ECR; FSE: 6CA) is pleased to announce the results of the Updated Mineral Resource Estimate (“MRE”) on its 100% owned flagship Cadillac Project, located in Val-d'Or (Abitibi, Quebec). The updated estimates include approximately 110,000 metres

(TSX:GUD), MONTREAL, Dec. 18, 2025 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, announced today that Health Canada has approved WYNZORA(R), a white uniform cream containing 0.05 mg/g of calcipotriol (CAL) and 0.5 mg/g of betamethasone dipropionate (BDP), indicated for the topical treatment of psoriasis vulgaris in adults

CINCINNATI, Dec. 18, 2025 (GLOBE NEWSWIRE) — Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse(R) On-Body Delivery System, today announced that the EMPAVELI(R) Injector, based on enFuse technology, has received marketing authorization from the Saudi Food and Drug Authority (SFDA). The authorization for the injector and syringe transfer system is

(NasdaqGM:NKLR), NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors today announced that it has been honored with a Special Mention for Sustainability at the 2025 United Nations Correspondents Association (UNCA) Awards Gala. Left to Right: Cesare Frepoli –